Header

UZH-Logo

Maintenance Infos

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial


Davies, D M; de Vries, P J; Johnson, S R; McCartney, D L; Cox, J A; Serra, A L; Watson, P C; Howe, C J; Doyle, T; Pointon, K; Cross, J J; Tattersfield, A E; Kingswood, J C; Sampson, J R (2011). Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clinical Cancer Research, 17(12):4071-4081.

Abstract

This study showed sustained regression of renal angiomyolipomas in patients with tuberous sclerosis or sporadic LAM receiving 2 years of sirolimus treatment. Possible effects on pulmonary function and neurocognition require further investigation.

Abstract

This study showed sustained regression of renal angiomyolipomas in patients with tuberous sclerosis or sporadic LAM receiving 2 years of sirolimus treatment. Possible effects on pulmonary function and neurocognition require further investigation.

Statistics

Citations

Dimensions.ai Metrics
145 citations in Web of Science®
162 citations in Scopus®
154 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

12 downloads since deposited on 07 Dec 2011
3 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Nephrology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2011
Deposited On:07 Dec 2011 12:23
Last Modified:17 Feb 2018 14:05
Publisher:American Association for Cancer Research
ISSN:1078-0432
OA Status:Hybrid
Publisher DOI:https://doi.org/10.1158/1078-0432.CCR-11-0445
PubMed ID:21525172

Download